Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Completed · Phase 3 · Has a placebo group

Conditions studied: Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with cancer who are receiving chemotherapy. It is not yet known whether epoetin alfa is more effective than a placebo in treating anemia in patients receiving chemotherapy. PURPOSE: Randomized double blinded phase III trial to compare the effectiveness of epoetin alfa with a placebo in treating anemia in cancer patients who are receiving chemotherapy.

Key facts

Study ID
NCT00003600
Run by
Alliance for Clinical Trials in Oncology
People needed
344
Starts
1998-12-01
Expected to finish
2010-01-01
Last updated by the study team
2016-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.